Comparison and Synergy of iVAC and CRISPR-Related Tumor Immune Strategies: Value Reassessment Under A Zero Genome Risk Reference
DOI:
https://doi.org/10.54097/pnqcf426Keywords:
Intratumoral vaccine chimeras; iVAC; CRISPR; Tumor vaccine; gene editing.Abstract
Intratumoral vaccine chimera (iVAC) is a protein level immune activation strategy that co delivers PD-L1 degrading agents and exogenous antigen peptides to tumor cell lysosomes through covalent nanobodies. It can complete antigen cross presentation while degrading PD-L1, and no off target mutations were observed in the detection as it does not involve genome editing. This article takes this as a zero-genome-risk reference and systematically compares existing data on iVAC and CRISPR tumor immune strategies from three dimensions: safety, persistence, and targeting depth. The results showed that the CRISPR strategy has accumulated preliminary clinical evidence in targeting intracellular driven mutations and long-term effectiveness of single editing (BRL-201 has a four-year complete response rate of 85.7% and an estimated five-year progression free survival rate of 40.6%), and off target detection methods continue to improve (TOPO seq found topology induced off target, and base edited NK cell products have obtained clinical approval); IVAC relies on pre stored CMV memory T cells, with transient modifications and a lack of long-term data. The existing evidence suggests that the two strategies may complement each other rather than replace each other in terms of security features, persistence, and depth of action. In the future, it is necessary to accumulate long-term human data on iVAC, promote the validation of CRISPR editing tools in solid tumors, and conduct clinical exploration of prospective combination therapies.
Downloads
References
[1] Topalian SL, Taube JM, Anders RA, et al. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy[J]. Nature Reviews Cancer, 2016, 16(5): 275-287. DOI: https://doi.org/10.1038/nrc.2016.36
[2] June CH, Sadelain M. Chimeric antigen receptor therapy[J]. New England Journal of Medicine, 2018, 379(1): 64-73. DOI: https://doi.org/10.1056/NEJMra1706169
[3] Lin MJ, Svensson-Arvelund J, Lubitz GS, et al. Cancer vaccines: the next immunotherapy frontier[J]. Nature Cancer, 2022, 3(8): 911-926. DOI: https://doi.org/10.1038/s43018-022-00418-6
[4] Ott PA, Hu Z, Keskin DB, et al. An immunogenic personal neoantigen vaccine for patients with melanoma[J]. Nature, 2017, 547(7662): 217-221. DOI: https://doi.org/10.1038/nature22991
[5] Han Y, Ma Y, Pei M, et al. Intratumoural vaccination via checkpoint degradation-coupled antigen presentation[J]. Nature, 2026, 637(8047): 654-662. DOI: 10.1038/s41586-025-09903-1. DOI: https://doi.org/10.1038/s41586-025-09903-1
[6] Jinek M, Chylinski K, Fonfara I, et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity[J]. Science, 2012, 337(6096): 816-821. DOI: https://doi.org/10.1126/science.1225829
[7] Doudna JA, Charpentier E. The new frontier of genome engineering with CRISPR-Cas9[J]. Science, 2014, 346(6213): 1258096. DOI: https://doi.org/10.1126/science.1258096
[8] Chow A, Perica K, Klebanoff CA, et al. Clinical implications of T cell exhaustion for cancer immunotherapy[J]. Nature Reviews Clinical Oncology, 2022, 19(12): 775-790. DOI: https://doi.org/10.1038/s41571-022-00689-z
[9] Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation[J]. Cell, 2011, 144(5): 646-674. DOI: https://doi.org/10.1016/j.cell.2011.02.013
[10] Duan M, Gao P, Zhang Y, et al. TOPO-seq reveals DNA topology-induced off-target activity by Cas9 and base editors[J]. Nature Chemical Biology, 2025, 21(6): 891-900. DOI: 10.1038/s41589-025-01867-7. DOI: https://doi.org/10.1038/s41589-025-01867-7
[11] Zhu SG, Huang XH, et al. Base editing of TIGIT reprograms CD155 signaling in natural killer cells to enhance cancer immunotherapy efficacy[J]. Cancer Research, 2026, 86(8): 1456-1471. DOI: 10.1158/0008-5472.CAN-24-0892. DOI: https://doi.org/10.1158/0008-5472.CAN-25-0733
[12] Chen AXY, Yap KM, Kim JS, et al. Rewiring endogenous genes in CAR T cells for tumour-restricted payload delivery[J]. Nature, 2025, 627(8007): 412-419. DOI: 10.1038/s41586-025-09212-7. DOI: https://doi.org/10.1038/s41586-025-09212-7
[13] Tan Q, et al. Long-term follow-up results of BRL-201 phase I study in relapsed/refractory B-cell non-Hodgkin lymphoma[C]. 67th ASH Annual Meeting, Orlando, FL, 2025. Poster presentation.
[14] T-knife Therapeutics. T-knife Therapeutics presents preclinical data on PRAME-targeted TK-6302 highlighting its potential as a promising, category-leading therapy [EB/OL]. (2025-11-07) [2026-06-10]. https://www.t-knife.com/technology/scientific-publications.
[15] T-knife Therapeutics. T-knife Therapeutics files clinical trial application for phase 1 ATLAS trial for TK-6302[EB/OL]. (2025-11-17) [2026-06-10]. https: // www.globenewswire.com/news-release /2025/ 11/ 17/ 3189058.
[16] Wang N, Luo Z, Liu C, et al. A HO-1 gene knockout using a NanoCRISPR scaffold suppresses metastasis in mouse models[J]. Nature Biomedical Engineering, 2025, 9(4): 445-458. DOI: 10.1038/s41551-025-01518-1. DOI: https://doi.org/10.1038/s41551-026-01854-w
[17] Ma L, Dichwalkar T, Chang J, et al. Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity[J]. Cell, 2023, 186(15): 3148-3165.e20. DOI: https://doi.org/10.1016/j.cell.2023.06.002
Downloads
Published
Issue
Section
License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

